A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Key Inclusion Criteria:

• 18 years of age or older

• Diagnosed with one of the following at least 3 months prior to screening:schizophrenia or schizoaffective disorder, bipolar disorder, or major depressivedisorder

• Diagnosed with at least mild neuroleptic-induced TD for at least 3 months prior toscreening

Key Exclusion Criteria:

• Have comorbid Parkinsonism or abnormal involuntary movement(s) that is moreprominent than TD

• Diagnosis of moderate or severe substance use disorder in the last 6 months

• History of long QT syndrome, cardiac arrythmia, or severe hepatic impairment